News
IMRN
1.970
+1.03%
0.020
Immuron completes strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) ...
GlobeNewswire · 11/16 12:00
Immuron CEO, Steven Lydeamore to present at AusBioInvest
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the tr...
GlobeNewswire · 10/26 10:00
Immuron Announces Strategic Investment In UK-Based Gut Health Company
Benzinga · 10/13 14:28
Immuron to acquire 17.5% stake in bowel disease drug maker Ateria
Seekingalpha · 10/13 11:03
Immuron strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, ex...
GlobeNewswire · 10/13 10:00
Immuron Announced £1.5M investment to Acquire 17.5% Stake Ateria Health
Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: o Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; o Option for further investment of £1.47m, expiring on 31 July 2023 • Ateria Health is a U.K.
Benzinga · 10/13 09:35
Immuron Plans $1.6 Million Investment in UK's Ateria Health
Immuron Plans $1.6 Million Investment in UK's Ateria Health
MT Newswires · 10/13 07:07
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Benzinga · 10/06 07:02
Why Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Pineapple Energy Inc. (NASDAQ: PEGY) shares jumped 104% to $2.9201. Shares of this low-float penny stock closed up about 80% on Tuesday.
Benzinga · 10/05 16:42
Australian stocks & ETFs rise after RBA’s smaller-than-expected interest rate hike
Stocks and exchange traded funds tied to the Australian market advanced in Tuesday's premarket trading in the U.S. The move came after the Reserve Bank of Australia raised interest rates by a lower-than-expected amount.The country's centra...
Seekingalpha · 10/04 13:22
Immuron Announces Master Service Agreement With Pharmaron CPC; Phase II Trial To Evaluate Efficacy Of Single Dose Regimen Of Travelan
Clinical Trial Master Service Agreement with US-based Pharmaron Executed Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a
Benzinga · 10/04 10:05
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Controlled Human Infection Model (CHIM...
GlobeNewswire · 10/04 10:00
Immuron Signs Master Service Agreement With Pharmaron CPC for Phase 2 Trial of Travelers' Diarrhea Therapy
Immuron Signs Master Service Agreement With Pharmaron CPC for Phase 2 Trial of Travelers' Diarrhea Therapy
MT Newswires · 10/04 06:38
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 08/31 12:07
Immuron CEO, Steven Lydeamore, to host an investor webinar
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invite...
GlobeNewswire · 08/29 11:00
Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape
Benzinga · 08/19 11:23
Immuron suspends research on COVID-19 program
Immuron (NASDAQ:IMRN) <a href="https://seekingalpha.com/pr/189109...
Seekingalpha · 08/19 10:33
Immuron Said Deprioritizing SARS-CoV-2 Research to Focus on Clinical Development of More Advanced Stage Therapeutic Drug Candidates
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.
Benzinga · 08/19 10:02
Immuron Update on IMM-124E SARS-CoV-2 Research
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today ...
GlobeNewswire · 08/19 10:00
Immuron's IND Application For Bacterial Infection Candidate Placed On Clinical Hold
Benzinga · 07/26 11:07
More
Webull provides a variety of real-time IMRN stock news. You can receive the latest news about Immuron Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IMRN
Immuron Limited is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of polyclonal antibodies that can address unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. Its flagship products include Travelan and Protectyn. Travelan is a licensed natural health product and is indicated to reduce the risk of Travellers’ Diarrhea. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn product helps to promote digestion and healthy gastrointestinal system health; support and maintain healthy liver function, and enhance immune defenses.